



IFPA

CONFERENCE

THE 7TH WORLD PSORIASIS
& PSORIATIC ARTHRITIS CONFERENCE 2024

June 27th - June 29th 2024

Conference Report

Published Oct 1st, 2024

EXECUTIVE SUMMARY

The 7th IFPA Conference (World Psoriasis & Psoriatic Arthritis Conference) took place in Stockholm, Sweden, from June 27 - 29, 2024. The conference, under the theme "Uncovering the Broad Spectrum of Psoriatic Disease," brought together more than 1000 delegates from over 75 countries and featured more than 190 abstracts and 50 high-level presentations. Accredited by the European Accreditation Council for Continuing Medical Education (EACCME), the event fostered global collaboration among medical professionals, patient organizations, and industry stakeholders.

Calling for breakthroughs

Established in 2006, the IFPA Conference (also known as the World Psoriasis & Psoriatic Arthritis Conference) provides a unique, cross-specialty platform. Medical and health professionals present frontline clinical research in dermatology, rheumatology and beyond. The IFPA conference has become a cornerstone event for medical and health professionals worldwide, fostering collaboration and showcasing cutting-edge research in dermatology, rheumatology, and related fields.

In the 2024 Conference attendees explored psoriatic disease from different perspectives by networking with patient leaders and industry representatives in attendance. The IFPA conference called for breakthroughs in research that will improve the understanding of all aspects of psoriatic disease.

Uncovering the Broad Spectrum of Psoriatic Disease

With Professor April W Armstrong as Conference President and Chair of the Scientific Executive Committee, the event effectively bridged gaps between disciplines, promoted patient-centered care, and laid the groundwork for future research and advocacy initiatives.

IFPA remains committed to advancing medical knowledge and improving patient care through future conferences and initiatives. Under the theme "Uncovering the Broad Spectrum of Psoriatic Disease," the IFPA 2024 conference aimed to foster international collaboration on research, advocacy initiatives, and awareness among medical professionals and industry stakeholders.

End.



Contents

Executive Summary.....	2
Introduction	4
Congress highlights	6
Main Scientific Program	9
Complementary and Civil Society Program Program	10
Continuing Medical Education (CME) Evaluation	11
Abstracts	13
Symposia.....	14
Collaboration scientific partner organizations IFPA.....	14
Communications and Social Media	16
IFPA Conference social program	17
About the IFPA Conference.....	19

Introduction

Conference Overview

The IFPA Conference (World Psoriasis & Psoriatic Arthritis Conference) is a global platform aimed at improving the understanding and integration of the latest developments in the field of psoriatic disease.

Principles of the IFPA Conference

The conference's purpose is to improve patient care by facilitating discussions and presentations on the current front line in clinical research and pathophysiological insights into all aspects related to psoriatic disease. By gathering medical professionals, researchers, and patient advocates, the IFPA Conference 2024 fosters an exchange of knowledge that drives advancements in treatment and care.

Guided by the principles of the World Health Organization (WHO) 2016 Global Report on Psoriasis¹, the IFPA Conference aligns its mission with recommendations to raise awareness of psoriasis and its associated comorbidities. This conference provides an essential forum to elevate global recognition of psoriatic disease and encourages collaboration on research and advocacy initiatives.

In May 2014, the 67th World Health Assembly officially adopted Resolution WHA 67.9. This year to celebrate a milestone and mark the 10th anniversary since the adoption of the WHO resolution on psoriasis at the conference social event.

Objectives:

- To increase **global recognition** of the seriousness of psoriatic disease and to develop a broader international perspective of psoriasis and psoriatic arthritis
- To **encourage collaboration** on developing future research and advocacy initiatives
- To **increase awareness** by medical professionals and industry of the role of IFPA and its members in assisting the medical advancement in psoriatic disease



¹ World Health Organization. (2016). Global report on psoriasis. World Health Organization. <https://iris.who.int/handle/10665/204417>

Conference leadership

Scientific Executive Committee



The Chair of the Scientific Executive Committee led by *Professor April Armstrong*, who was the 7th IFPA Conference President. Dr. Armstrong is a Professor and Chief of Dermatology at the University of California, Los Angeles (UCLA), where she is recognized as an internationally renowned expert in inflammatory skin diseases, including psoriasis. In addition to her role at UCLA, Dr. Armstrong is the Co-Director for Network Resources at the UCLA Clinical and Translational Research Institute.

Supporting Dr. Armstrong in this multidisciplinary leadership team: *Professor Ulrich Mrowietz*: Founder of the Psoriasis Centre at the University Medical Centre Schleswig-Holstein in Germany. His expertise significantly contributes to the understanding and treatment of psoriasis. And *Professor Laura Coates*: an Associate Professor and Senior Research Fellow at the National Institute for Health and Care Research in Oxford, England. Dr. Coates research focuses on therapeutic strategies for psoriatic arthritis, providing essential rheumatological expertise to the team. Dr. Coates providing the rheumatological expertise in this multidisciplinary leadership team

Barbra Bohannan served as the Conference Secretary. She is also the Coordinator for Policy, Advocacy, and Research at Psoriasisförbundet, Psoriasis Association Sweden.

Developing a Scientific Program

We shared knowledge, engaged in meaningful conversations, and highlighted significant achievements in the prevention, diagnosis, and treatment of psoriatic disease. The IFPA conference serves as a platform to focus on future research and advance care for all persons living with psoriatic disease.

Professor April Armstrong, Conference President

The Scientific Executive Committee is responsible for developing the Scientific Program and bringing together scholars, researchers, and patient advocates from across the globe. To complement the keynote lectures and plenary presentations, the Scientific Program also included oral abstract presentations. This provides an opportunity for individuals to showcase their research findings and contribute to the congress proceedings.


Congress highlights

Global representation

The conference brought together over 1000 delegates across 77 countries, including hospitals, universities, and pharmaceutical companies, reflecting a collective commitment to psoriatic disease research, novel treatments, and advocacy.

This diverse representation highlights the significance of multidisciplinary approaches in addressing psoriasis through collaboration among experts in dermatology, rheumatology, immunology, genetics, and psychology. The IFPA conference is special because it focuses on a multidisciplinary approach, making it different from other similar congresses.

Representation across the globe



Attendance by Country


Most attendees were from the Americas, Europe and South America region, specifically the United States of America and Canada. The number of countries represented in 2024 has increased by 15% compared to the virtual meeting held in 2021. This increase follows a baseline of 66 countries represented at the 2021 virtual conference.

Due to the pandemic, the last IFPA conference was held in fully virtual format. The increase in attendees underscored the growing need for physical interaction, even in a digitally connected world.

Over 60% of all attendees were healthcare professionals.

Increase virtual attendees from Asia Pacific region and Middle East & North Africa Region

Top 15 countries with the highest representation based on attending organizations




The emphasis on in-person engagement remains crucial for fostering collaboration and community within the field.

A growing regional engagement.

Participation trends in recent conferences indicate a significant increase in representation from **Sub-Saharan Africa**, particularly among government and medical associations committed to improving healthcare systems. The 2024 conference marked a milestone with heightened engagement from the **Middle East and North Africa (MENA)** region, especially from organizations in the United Arab Emirates and Saudi Arabia. This growing involvement suggests a shift towards greater regional collaboration in addressing shared health challenges.

Health Care Providers



Healthcare Physicians: A Breakdown by Specialization in percentage

Attendee Representation Across Organizations

Attendees represented a wide range of organisations. HealthCare providers, working in hospitals, wellness centers, skincare clinics, and educational institutions, accounting for over 60%. Pharmaceuticals and biotechnology representatives made up 15% of the attendees, classified as non-healthcare providers.

	Health Facilities
	Pharmaceuticals and
	Biotechnology Co.
	Education institutions
	Non-Profits, Medical Associations, Charities, Public
	Organisations, CCOs) Health Research, Biotech and
	Innovation Co.
	Healthcare Media, Publishers, Communications
	Consultancy Companies
	Others

Patients and non-profit patient organizations represented around 20%, while government agencies comprised less than 10%. The remaining attendees were from media publishers, and scientific communications.



Images: Opening ceremony and scientific program

Main Scientific Program

IFPA's conference meets the highest standards of developing, delivering, and harmonizing continuing medical education (CME) and has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®). CME credits are 12.0 for this conference.

IFPA recognizes that attendees of the IFPA conference need to fulfill the necessary requirements to maintain their professional competence and enhance their knowledge and skills within the field of healthcare. Annual CME requirements for licensure and recertification in various countries.

The Scientific Executive Committee developed the Scientific Program with the objective of uniting scholars, researchers, and patient advocates from around the world.

Program highlights

The Scientific Program featured several key sessions designed to explore the latest advancements in psoriatic disease.

The faculty, composed of leading experts in their respective fields, was chaired primarily by scientific experts Key Opinion Leaders (KOLs) to ensure the highest standard of the program. This discussion provided valuable insights into gaps in current treatment and care strategies.

Keynote Lectures

- ***Advances in Genetics and Immunology of Psoriasis*** by Wilson Liao, MD, PhD,
- ***Can We Prevent Psoriatic Arthritis?*** by Laura Coates, MD, PhD.
- ***Advances in Genetics and Immunology of Psoriatic Arthritis.*** Presentation by Carl Goodyear, MD, PhD

Hot Topics. Debates. Panel Discussion

The program also included hot topic debates

- ***Immunopathogenesis – On the Skin or Within?*** by Ulrich Mrowietz, MD and Jens Schröder, MD PhD
- ***Preventing Psoriatic Arthritis in Psoriasis – Where Is the Evidence?*** presentation by Alexis Ogdie, MD.PhD

A special session on the ***Impact of Lifestyle Interventions in Psoriatic Disease*** by Wendy Hall, MD, PhD, focusing on the influence of lifestyle factors in managing psoriatic disease.

Joint panel discussion focused on ***Uncovering the unmet needs in psoriatic disease***, with panelists including Patient Experts Josef De Guzman and Silvia Fernández Barrio together with Julia Yu-Huei Huang, MD, Alexis Ogdie, MD. moderated by Joseph Merola, MD PhD

The program aligned with the congress theme and featured a series of keynote lectures, plenary presentations, and debate-style discussions on hot topics, as well as oral abstract presentations.

Complementary and Civil Society Program Program



A joint panel discussion marked the 10th anniversary of the World Health Organization (WHO) Resolution on Psoriasis (2014).

The Complementary Program is designed primarily for allied health professionals, skincare nurses, pharmacists, physician assistants, physiotherapist, patient leaders, and industry representatives, and was held to the highest standards at the conference.

The Complementary Program continues to serve as a critical platform for collaboration and knowledge-sharing, ensuring that healthcare professionals and patient leaders stay at the forefront of innovations in psoriatic disease care. The program provided a reflective space on the global ongoing efforts to address psoriatic disease, associated comorbidities

This year's program focused on three central themes:

- Improving Quality of Life in Psoriatic Disease – Emphasis was placed on mental health, lifestyle management, and the comorbidities associated with psoriatic disease. Speakers underscored the need for a holistic approach to enhance patient well-being.
- Access for All – This theme addressed unmet needs, focusing on equitable access to treatment and improving patient care. Discussions highlighted the importance of overcoming barriers to healthcare
- The Broad Spectrum of Psoriatic Disease – Attendees discussed the diverse manifestations of psoriatic disease, gaining a deeper understanding of its broad spectrum and associated challenges.

The speakers, including clinicians, allied health professionals, and patient advocates, presented impactful discussions, and reflecting commitment to advancing knowledge and patient care in the field of psoriatic disease.

The program was led and co-chaired by: Prof. Mahira El Sayed and Prof. Claudia de la Cruz.




Prof. Mahira El Sayed Chair of The Complementary Program - Gives Opening Remarks

PROGRAM

Continuing Medical Education (CME) Evaluation

Main Scientific Programme

■ Excellent
 ■ Fair
 ■ Good
 ■ Very Good



Evaluation on the quality of the main scientific program

The evaluation survey with over 400 respondents were healthcare providers including dermatologists, rheumatologists, and researchers. Overall, the response was positive with participants noting that the dual approach facilitated knowledge sharing across specialties, with over 70% rating the program as excellent or very good. And nearly all respondents agreed that the program was relevant and has an impact on clinical practice


The best aspects noted were the quality of the speakers, the content, and the discussions.

Attendees particularly appreciated the interactions between dermatologists and

rheumatologists, as well as the engagement between the panel and the audience.


New presentations receiving high ratings included topics such as disease pathophysiology, psoriasis and pregnancy, and new treatments and drugs.

Relevance of the event - program



Relevance of the scientific program- Over 95% agree that the program was useful

Overall perspective on the impact of the event on clinical practice



Impact of conference on clinical practice

The collaborative approach between specialties was noted to improve the overall experience and deepened understanding across fields. In addition, discussions on clinical cases provided practical applications



The Complementary Program Co-Chaired by: Prof. Mahira El Sayed and Prof. Claudia De La Cruz at the opening ceremony in remembrance Of Dr. Hoseah Waweru former program chair and president of IFPA.

'The 2024 IFPA conference showcased our progress in treating the whole person, highlighting the complex nature of psoriatic disease and inspiring hope for improved quality of life.'

Barbra Bohannon, Conference Secretary

'During the past three days, we have united the psoriatic disease community and truly covered the broad spectrum of this disease. We are bridging gaps between disciplines, specialty groups, and the patient community, moving from knowledge to action'.

Frida Dunger, Executive Director IFPA

'This year's theme 'Uncovering the Broad Spectrum of Psoriatic Disease' at this conference emphasized patient-focused research and encouraged collaborations on future advocacy initiatives.'

Ingvar Ágúst Ingvarsson, Acting President of IFPA

'I liked engaged interactions across all specialties and the opportunity to write in questions at any time in the Conference mobile app.'

Delegate, IFPA Conference

Abstracts

This year's conference witnessed a remarkable increase in abstract submissions, with over 190 abstracts received. Among the submitted abstracts, a notable number achieved and were recommended for oral presentations. This trend of increasing quality in submissions is a positive development that has been consistently observed over the past few meetings. IFPA Conference are now published in the [Acta Dermato-Venereologica](#) with manuscripts submitted focused on Psoriatic disease and comorbidities²

The poster area at the IFPA conference was a lively space for sharing ideas and research. Attendees explored a wide range of posters featuring new findings in dermatology and venereology. Each poster created a chance for conversations and networking, helping researchers and clinicians connect and share knowledge. A highlight of the conference was the recognition of exceptional posters through the Poster Prize.



Poster Area IFPA Conference 2024



Delegates at the poster section at the IFPA Conference



Prof Philip Mease, IFPA Scientific advisory board member at IFPA Conference. Dr Mease was also oral abstract presenter

² Acta Dermato Venereologica ActaDV. Advances in dermatology and venereology <https://medicaljournalsweden.se/actadv/article/view/40937/46598>

Symposia

Since its launch in 2006, industry partners have been crucial in developing the symposium's program. They provide healthcare professionals with the latest insights and advancements in dermatology, rheumatology and cardiology treatments through specialized sessions.

The industry exhibition area featured a digital platform that enabled participants to connect with exhibitors and discover innovative medical products and services.

JOIN US AT THE IFPA CONFERENCE
STOCKHOLM, SWEDEN




PROGRAM FACULTY


April Armstrong, MD, MPH


Vinod Chandran, MD, PhD


Claudia de la Cruz, MD


Mahira El Sayed, MSc, MD


Oliver Fitzgerald, MD


Philip Mease, MD


Joseph Merola, MD, MMSc


Bruce Strober, MD, PhD

June 28, 2024 | 17:45 - 18:45 CEST | The 7th World Psoriasis and Psoriatic Arthritis Conference (IFPA) | Stockholm Waterfront Congress Centre, Room C1/C2 | Stockholm, Sweden

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) & International Psoriasis Council (IPC) held joint Symposium:

Pso Bold: Tackling Challenging Issues in Psoriasis and Psoriatic Arthritis

Collaboration scientific partner organizations IFPA



Advancing Knowledge. Improving Care.




International League of Dermatological Societies
Skin Health for the World



The International Registry for Health Care Providers Reporting COVID-19 Outcomes in Individuals with Psoriasis.

SPONSORS, EXHIBITORS AND SYMPOSIUM HOLDERS

Diamond sponsor



Platinum sponsors



Gold sponsors



Silver sponsors



Bronze sponsors



Exhibition




Symposium



With Thanks To:

IFPA 2024 conference sponsors and partners for their invaluable support in making this conference a success. Your commitment to advancing the field of dermatology and enhancing the experience for attendees is truly appreciated.



Exhibition Area and Industry Area

Communications and Social Media




Press release reach

Press release and marketing not only informed attendees but also reached a broader audience, raising awareness about psoriatic disease. Overall, the press release played a crucial role in the success of the conference and its contributions to the field, making it an essential tool for ongoing communication efforts.

PR PR Newswire
IFPA Celebrates Success of the 7th IFPA Conference 2024
PRNewswire/ -- IFPA (The International Federation of Psoriasis Associations) concluded its highly anticipated 7th IFPA Conference on World...
1 Jul 2024


C Canada Newswire
Don't Miss Out - Join the 7th IFPA Conference: Uncovering the Broad Spectrum of Psoriatic Disease
CNW/ -- IFPA is delighted to announce the 7th IFPA Conference set to take place from June 27th to June 29th, 2024, in the picturesque city...
11 Apr 2024

C Cision News
IFPA Conference 2024
IFPA Conference 2024. Wed, Jul 20, 2022 11:21 CET. IFPA Conference 7th WPPAC
IFPA Conference 2024 2024 - Low resolution · Medium resolution.
20 Jul 2022



Press Release image from newswire

You reposted
Cristina Macía @reumacia · Jun 29
Time to return home! 🇸🇪 🇩🇪 🇪🇸
What a great congress! #IFPAConference2024 @PsoriasisIFPA



Social media: Minute-by-minute coverage of the latest insights, discussions, and breakthroughs in psoriatic disease.

Lih Eder @lihi_eder · Jun 29
I was a pleasure discussing gaps in PsA diagnosis at the #IFPAConference2024 in beautiful Stockholm 🇸🇪

IFPA @PsoriasisIFPA · Jun 29
@lihi_eder sheds light on the challenges: 'There are still significant gaps in diagnosis of PsA. We know that delayed diagnosis is associated with worse outcomes.' Let's bridge those gaps for better patient care! #IFPAConference2024



Twitter engagement with minute-by-minute updates

You reposted
International Psoriasis Council @IpcPs

Thanks to the #IPC & @GrappaO communities for supporting our joint symposium, Pso Bold: Tackling Challenging Issues in Psoriasis & Psoriatic Arthritis, at #IFPA2024. Together, we can advance the missions & goals of both our communities!

More #IPCEvents:
psoriasisCouncil.org/calendar-of-ev...



8:02 PM · Jul 1, 2024 · 243 Views

IFPA Conference social program

In celebration of the tenth anniversary of the World Health Assembly Resolution on Psoriasis, the IFPA Conference will host a special social program and dinner. This event marks a significant milestone in the journey towards improving psoriasis care.

The social event brings together stakeholders from diverse sectors to celebrate progress made in psoriatic disease care and address ongoing challenges. By emphasizing the importance of continuous research, innovation in treatment development, and the creation of inclusive policies, this partnership aims to drive substantial advancements in the field.



Image: Source Conference website: Attendees enjoy dinner at Skansen Stockholm vibrant networking opportunities and engage in meaningful conversations during the



Image source Conference website: Attendees gather at the Stadhuset Stockholm Sweden, home of the Nobel Prize Dinner, a memorable highlight of the social program at the IFPA Conference 2024, celebrating connections and collaboration.

<https://conference.ifpa-pso.com/>

About the IFPA Conference

- **Conference name:** IFPA Conference 2024
- **Theme:** “Uncovering the Broad Spectrum of Psoriatic Disease.”
- **Date:** June 27-29, 2024
- **Venue:** Stockholm Waterfront Congress Centre, Stockholm, Sweden
- **Attendees’:** Dermatologists, rheumatologists, researchers, general practitioners, and allied health professionals with an interest in psoriasis and psoriatic arthritis. Patient leaders, advocates and Health officials



Website: www.ifpaconference.com X: @PsoriasisIFPA, #IFPAconference2024

Acknowledgement

Faculty and Scientific Advisory Committee members who continue ensure that the conference is of high quality and standard.

Scientific Executive Committee

- *Conference President*
April Armstrong, MD, PhD California, USA
- *Chair in Dermatology*
Ulrich Mrowietz, MD, Dr Med Kiel, Germany
- *Co-Chair in Rheumatology*
Laura Coates, MD, PhD Oxford, United Kingdom

Complementary Program

- *Former Chair to the complementary program*
Hoseah Waweru, MD Nairobi, Kenya
- *Incoming Chair to the complementary program*
Mahira El Sayed, MD, PhD Cairo, Egypt
- *Co-chair to the complementary program*
Claudia de la Cruz, MD, PhD, Santiago Chile

IFPA Scientific Advisory Board

- Peter van de Kerkhof, MD, PhD, The Netherlands
- Mark Lebwohl, MD, PhD, USA
- Jörg Prinz, MD, PhD, Germany
- Mona Ståhle, MD, PhD, Sweden
- Philip Mease, MD, PhD, USA
- Christopher Ritchlin, MD, PhD, USA

Organizing Committee; IFPA Board and Secretariat



About IFPA ; Founded in 1971, IFPA is the global organization uniting all people living with psoriatic disease – regardless of where they live, what type of psoriatic disease they have, or how it impacts their lives. IFPA’s members represent over 60 million people living with psoriatic disease

Find out more about IFPA <https://ifpa-pso.com/global-actions/>

Find out more about the 8th IFPA Conference <https://conference.ifpa-pso.com/>

